[Tobramycin inactivation by cefotaxime in patients with terminal-stage chronic kidney failure].
Sedykh
N P
NP
Sinukhin
V N
VN
Darenkov
A F
AF
D002439:Cefotaxime / Q000493:pharmacokinetics / Q000494:pharmacology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D012016:Reference Values; D013997:Time Factors; D014031:Tobramycin / Q000037:antagonists & inhibitors* / Q000493:pharmacokinetics
D002439:Cefotaxime; D014031:Tobramycin
Inaktivatsiia tobramitsina tsefotaksimom u bol'nykh s khronicheskoĭ pochechnoĭ nedostatochnost'iu v terminal'noĭ stadii.